Clinical trials: Pancreatic Adenocarcinoma Resectable
Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma
FAZA PET/MRI Pancreas
This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer
- Trial name
- NCT04395469
- Testing
- 18F-FAZA
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer Non-resectable
A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
This clinical study aims to evaluate the safety and tolerability of intra-arterial Yttrium-90 (90Y) glass microspheres in patients with unresectable pancreatic adenocarcinoma.
- Trial name
- NCT07898683
- Testing
- Transarterial Radioembolization
- Where
- Russia
- Volunteers
- 12 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable
A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)
Pancreatic cancer exhibits significant heterogeneity, which poses a major challenge in selecting the best treatment for patients from the very beginning of care.
- Trial name
- PRODIGE 104 B (NCT07592819)
- Testing
- mFOLFIRINOX (modified FOLFIRINOX)
- Volunteers
- 367 people
- Sponsor
- Institut Paoli-Calmettes
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
The goal of this prospective observational study is to learn about the clinical utility of dynamic ctDNA-based Minimal Residual Disease (MRD) monitoring in patients with borderline resectable pancreatic cancer undergoing…
- Trial name
- MRD (NCT07080021)
- Testing
- Standard Reagents, Pancreatic Cancer
- Where
- 2 sites in China
- Volunteers
- 119 people
- Sponsor
- Ruijin Hospital
Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being…
- Trial name
- PaTK02 (NCT02446093)
- Testing
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy
- Where
- 3 sites in United States, Mexico
- Volunteers
- 54 people
- Sponsor
- Candel Therapeutics, Inc.
Pancreatic Cancer
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
This platform trial will evaluate various immunotherapy combinations given in the neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal adenocarcinoma.
- Trial name
- NCT02451982
- Testing
- Cyclophosphamide, GVAX pancreatic cancer, Nivolumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Pancreatic Adenocarcinoma
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal…
- Trial name
- NCT04130399
- Testing
- Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
- Where
- United States
- Sponsor
- Indiana University
Pancreatic Adenocarcinoma
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer.
- Trial name
- NCT01206296
- Testing
- Intraperitoneal Gemcitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medstar Health Research Institute
Pancreas Cancer, Pancreatic Cancer
Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)
This study is looking at determining the maximum safe dose of CyberKnife when given with chemotherapy for unresectable adenocarcinoma of the pancreas.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma
- Trial name
- NCT02707328
- Testing
- Gemcitabine, nab-paclitaxel, CyberKnife
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cooper Health System
Pancreatic Cancer, Pancreatic Cancer Non-resectable
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06361030
- Testing
- surufatinib combined with gemcitabine plus nab-paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Resectable Pancreatic Adenocarcinoma
Identify microRNAs in Cachexia in Pancreatic Carcinoma
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
- Trial name
- SCC-miRPanCa (NCT05275075)
- Testing
- Pancreatic cancer microRNA and messenger RNA expression.
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery
This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.
- Trial name
- PANCREAS (NCT04452461)
- Testing
- mFOLFIRINOX, Gemcitabine / Nab-paclitaxel
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Hamilton Health Sciences Corporation
Pancreatic Cancer
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable…
- Trial name
- NCT05604560
- Testing
- Tislelizumab, SX-682
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lei Zheng
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00536874
- Testing
- gemcitabine hydrochloride, oxaliplatin, protein expression analysis
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma
Pancreatic cancer (PC) is expected to be the third leading cause of cancer death in Canada in 2019 [1]. Localized pancreatic cancer may be classified as resectable, borderline resectable, or locally advanced.
- Trial name
- ANSR-PDAC (NCT04915417)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR)
- Volunteers
- 30 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pancreas Cancer, Pancreas Neoplasm
Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy
Pancreaticoduodenectomy (PD) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality.
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreatic Fistula, Pancreas Adenocarcinoma
- Trial name
- POPF (NCT07022015)
- Testing
- pancreaticoduodenectomy procedure
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Minia University
Pancreatic Cancer
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
This is a randomized phase II trial that will examine the ability of the hydroxychloroquine to improve the clinical activity of a pre-operative regimen of gemcitabine and nab-paclitaxel in subjects with potentially resectable…
- Trial name
- NCT01978184
- Testing
- gemcitabine, abraxane, hydroxychloroquine
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Nathan Bahary, MD
Pancreatic Neoplasms, Pancreatic Adenocarcinoma
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
This single-center, prospective proof-of-concept study is designed to evaluate the surgical outcomes and clinicopathologic results of neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with perioperative…
- Trial name
- NCT02850874
- Testing
- Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma
Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Oesogastric and pancreatic adenocarcinomas are poor-prognosis cancers. Incidence of pancreatic cancer drastically increases to such an extent that it will become the second cause of cancer's mortality by 2030.
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Adenocarcinoma, Resectable Esophageal Cancer
- Trial name
- HEPATOXALI (NCT06649474)
- Testing
- assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle…
- Trial name
- NCT02562716
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride
- Where
- 807 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network